Opus Genetics (IRD) awards 400,000 RSUs to chief scientist

Rhea-AI Filing Summary

Opus Genetics, Inc. reported an equity award to its Chief Scientific & Dev. Officer, Jayagopal Ashwath. On January 22, 2026, he received 400,000 shares of common stock at a price of $0 per share, reported as a grant of restricted stock units. These RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, as long as he continues in service. Following this grant, he beneficially owns 525,807 shares of Opus Genetics common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jayagopal Ashwath

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific & Dev. Ofc.

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		400,000(1)	A	$0	525,807	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service.

	/s/ Amy Rabourn, by Power of Attorney	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRD report for Jayagopal Ashwath?

IRD’s Chief Scientific & Dev. Officer, Jayagopal Ashwath, was granted 400,000 shares of common stock on January 22, 2026, reported as restricted stock units.

What type of equity did Opus Genetics (IRD) grant in this Form 4?

The filing reports a grant of restricted stock units (RSUs) covering 400,000 shares of common stock, with no cash price ($0 per share).

How do the 400,000 RSUs for IRD’s officer vest?

The 400,000 RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, subject to continued service.

How many Opus Genetics shares does the reporting person own after this grant?

After the reported grant, Jayagopal Ashwath beneficially owns 525,807 shares of Opus Genetics common stock in direct ownership.

Is the reported ownership in IRD held directly or indirectly?

The Form 4 shows the 525,807 shares of common stock as held under direct (D) ownership by the reporting person.

Did the IRD executive pay cash for the 400,000-share RSU grant?

No cash consideration is reported; the transaction lists a price of $0 per share, consistent with a compensatory grant of restricted stock units.